<DOC>
	<DOCNO>NCT00904852</DOCNO>
	<brief_summary>This safety study tandutinib combination temozolomide bevacizumab people receive radiation therapy temozolomide treatment . This study determine maximum safe dose tandutinib combine temozolomide bevacizumab evaluate safety combination treatment .</brief_summary>
	<brief_title>Safety Study Combination Tandutinib With Temozolomide Bevacizumab After Radiation Temozolomide Patients With Newly Diagnosed With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Diagnosis glioblastoma multiforme Received radiotherapy glioblastoma multiforme Patients previous treatment glioblastoma multiforme ( except surgery , radiation temozolomide therapy ) Females postmenopausal least 1 year prior screen visit 18 year age old Other brain cancer diagnose glioblastoma multiforme female patient lactate pregnant HIV positive and/or active infection require therapy Known hepatitis B hepatitis C infection Diagnosed treated cancer within 2 year first dose History cardiovascular condition and/or vascular disease Allergic component bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>